[iv] Postmenopausal osteoporosis has a huge impact on healthcare budgets, which are already expected to double for osteoporosis by the year 2050.
What does PMO stand for?
PMO stands for Postmenopausal Osteoporosis
This definition appears frequently and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of PMO
We have 133 other meanings of PMO in our Acronym Attic
- Performance Management Office
- Personnel Management Officer (US DoD)
- Pisses Me Off
- Planned Maintenance Outage
- Plant Maintenance Order
- Plymouth (Amtrak station code; Plymouth, NH)
- Polaris Material Officer
- Police Motorcycle Officer
- Porn, Masturbation, Orgasm
- Portfolio Management Officer
Samples in periodicals archive:
Vitamin K2, raloxifene, and bisphosphonates, such as etidronate, alendronate, and risedronate, are widely used in the treatment of postmenopausal osteoporosis in Japan.
Already approved as a once-yearly infusion for the treatment of women with postmenopausal osteoporosis and men with osteoporosis, as well as for the treatment of Paget's disease of the bone and the prevention and treatment of glucocorticoid-induced osteoporosis, Reclast is now the first and only approved single-dose, biyearly infusion for the prevention of postmenopausal osteoporosis, according to the Novartis statement.
Postmenopausal Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017 Summary The report is an essential source of information and analysis on the global Post Menopausal Osteoporosis Therapeutics market.
Calcitonin has a long history of safety for postmenopausal osteoporosis treatment, and potential availability of this once-daily oral formulation could make it a useful new option for osteoporosis patients and their physicians.
The two-year double-blind study included 88 women over the age of 50 with postmenopausal osteoporosis who were randomised to treatment with either Protelos 2g daily or alendronate 70mg per week.
Earns Milestone Payment from Wyeth SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its partner Wyeth (NYSE:WYE) has received approval from the European Commission (EC) for CONBRIZA[TM] (bazedoxifene), a selective estrogen receptor modulator (SERM) for the treatment of postmenopausal osteoporosis in women at increased risk of fracture.
Completes Patient Dosing in ORACAL Trial; Results Expected in Early Spring -- -- Enrollment Opened in New Phase II Postmenopausal Osteoporosis Prevention Trial -- PHILADELPHIA, Feb.